Advertisement
Advertisement
-
TOPIC

Innovent Biologics

(信达生物)

Innovent Biologics
信达生物
Established in 2011, Innovent Biologics is a biotechnology company that develops, manufactures and commercialises medicine for oncology, cardiovascular and metabolic diseases, autoimmune diseases and ophthalmology. The Suzhou-headquartered company was listed on the Hong Kong stock exchange on October 31, 2018.
Made in China 2025

China’s pharmaceutical industry transforms into a global innovation powerhouse

The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time.

Ascletis trial shows drug candidate ASC47 boosts semaglutide weight loss effect

‘China’s Ozempic’ pioneer inks deal with JD Health for online distribution

China’s weight loss drugs market could grow to US$5.6 billion by 2035, according to Goldman Sachs.

China’s weight-loss drug market to lure entrants as Eli Lilly, Novo dominate

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley says.

videocam
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement